Exagen (NASDAQ: XGN) — Perfil da empresa, notícias e dados financeiros
Exagen improves autoimmune disease care through advanced diagnostic and therapeutic solutions.
Exagen
Exagen (NASDAQ:XGN) is a health services company focused on transforming the care continuum for patients suffering from autoimmune diseases. By deploying a combination of unique testing services and proprietary technologies, Exagen aims to empower physicians with precise diagnostic, prognostic, and therapeutic solutions. The company is committed to advancing the field of autoimmune diagnostics through ongoing research and development projects, striving to uncover new insights and innovations that can improve patient outcomes. Exagen's principal objective is to enhance the quality of life for those affected by autoimmune conditions by providing accurate, early detection and facilitating targeted treatment strategies.
Resumo
Operações
Produtos e/ou serviços de Exagen
- AVISE CTD test for differential diagnosis of connective tissue diseases, aiding in accurate diagnosis of lupus and other autoimmune diseases.
- AVISE Lupus test, designed specifically to aid in the diagnosis of systemic lupus erythematosus (SLE), offering high sensitivity and specificity.
- AVISE APS, a testing solution for antiphospholipid syndrome (APS), providing vital information for risk assessment and management of this autoimmune disorder.
- AVISE SLE Monitor, a comprehensive monitoring tool for managing systemic lupus erythematosus, enabling personalized treatment adjustments.
- AVISE MCV, a biomarker test for measuring the activity of rheumatoid arthritis, assisting in disease management and treatment decision-making.
- AVISE PG, a pharmacogenetic testing service that guides the effective use of certain medications in individual patients, aiming at personalized medicine.
equipe executiva do Exagen
- Tina S. NovaExecutive Chairman of the Board of Directors
- John AballiCEO, President & Director
- Jeffrey G. BlackCFO & Corporate Secretary
- Michael MahlerChief Scientific Officer
- Tina JacobsenVice President of Investor Relations
- Prashanti ReddyChief Medical Officer
Principais indicadores financeiros
Resultados divulgados pela Exagen, em USD.
- Cap. de mercado
- 188,5 mi
- Receita (TTM)
- 71,1 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.8
- Dividend yield
- —
- Margem de lucro
- -26.6%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 66,6 mi | -14,1 mi | -20 mi | |
| 55,6 mi | -13,6 mi | -15,1 mi | |
| 52,5 mi | -22,8 mi | -23,7 mi | |
| 45,6 mi | -46,1 mi | -47,4 mi |